Business / Finance

RSS

Radiation Therapy Services to issue $50M of 9-7/8% Senior Subordinated Notes due 2017

Radiation Therapy Services Holdings, Inc.announced today that its wholly owned subsidiary, Radiation Therapy Services, Inc., has agreed to issue an aggregate principal amount of $50 million of 9-7/8% Senior Subordinated Notes due 2017.

24 Jan 2011

Novartis enters definitive merger agreement to acquire Genoptix

Genoptix, announced today that it has entered into a definitive merger agreement to be acquired by Novartis. Under the terms of the merger agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at USD$25.00 per share.

24 Jan 2011

Teva Pharmaceutical announces entry into new three-year credit facility

Teva Pharmaceutical Industries Ltd. announced today that it has entered into a new three-year, $1.5 billion unsecured revolving credit facility, which replaces and expands existing credit lines at terms that are more favorable to Teva.

24 Jan 2011

CRI, Oncovir sign new investment agreement to produce immunological stimulant

Cancer Research Institute, a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund, a joint initiative with the Ludwig Institute for Cancer Research, has completed a new investment agreement with Oncovir, a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol- (Poly-ICLC).

24 Jan 2011

Novation, Lantheus Medical to distribute ABLAVAR and DEFINITY diagnostic imaging agents

Lantheus Medical Imaging, a worldwide leader in diagnostic medical imaging, today announced a national contract with Novation for ABLAVAR and DEFINITY Vial For Injectable Suspension, providing increased access to these important diagnostic imaging agents for health care providers served by Novation.

23 Jan 2011

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).

21 Jan 2011

Possible hospital merger in Mass. could accelerate trend toward consolidation

News outlets also report on another hospital merger as well as how a Minnesota psychiatric hospital gathered the necessary funds and support to be built.

21 Jan 2011

Pharmasset prices underwritten public offering of 3,300,000 shares of common stock

Pharmasset, Inc. announced today the pricing of an underwritten public offering of 3,300,000 shares of its common stock at an offering price of $46.33 per share. Of the shares being sold, Pharmasset is selling 2,300,000 shares and the selling stockholders are selling 1,000,000 shares. Pharmasset expects to receive net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $101.5 million.

21 Jan 2011

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements within its Global Operations. In conjunction with the meeting, the Company provided its preliminary 2011 financial and long term growth forecasts.

21 Jan 2011

Jiangbo Pharmaceuticals reaches settlement with debenture holders

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.

21 Jan 2011

SQI fourth quarter net loss increases to $2,621,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the fourth quarter and year ended September 30, 2010.

21 Jan 2011

Intellipharmaceutics receives purchase agreement commitments for $12,000,000

Intellipharmaceutics International Inc. today announced that it has received purchase agreement commitments from institutional investors to provide the Company with approximately US$12,000,000 in gross proceeds through the sale of its common stock and warrants.

21 Jan 2011

Surgery Partners to acquire NovaMed for $214 million

NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.

21 Jan 2011

inVentiv Health to acquire Campbell Alliance and i3

inVentiv Health, Inc., a leading provider of outsourced clinical development, launch and commercialization services to the global healthcare industry, today announced that it has signed a definitive agreement to acquire Campbell Alliance, a leading management consulting firm specializing in serving the pharmaceutical and biotech industries. Yesterday, inVentiv announced that it has signed a definitive agreement to purchase i3 from Ingenix.

From Thermo Fisher Scientific Inc. 21 Jan 2011

WSJ: Insurers' profits on the rise

Health insurers' fourth-quarter reports will provide an early glimpse into how much wind the health overhaul could take out of plans' profits—and, so far, Wall Street estimates don't look all that bad for the industry (Johnson, 1/20).

21 Jan 2011

The Ensign Group to purchase CHRISTUS St. Joseph Villa located in Utah

The Ensign Group, the parent company of the Ensign group of skilled nursing, rehabilitative care services, hospice care and assisted living companies, announced today that it has agreed to purchase CHRISTUS St. Joseph Villa, a continuing care retirement community located in Salt Lake City, Utah, and the CHRISTUS Marian Center, a behavioral health center operated within St. Joseph Villa.

21 Jan 2011

Northeast Ohio healthcare sector companies attracted $132 million in investments in 2010

In 2010, 62 Northeast Ohio companies collectively raised $221 million from venture capitalists and angel investors, an increase of 121 percent over the amount raised by companies in 2009. The growth rate of dollars invested in regional companies is higher than recently released data from Thomson Reuters showing a 19 percent increase in dollars invested nationally.

21 Jan 2011

Fresenius Medical Care to sell $500 million and €300 million senior notes

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced its intention to sell US$500 million of senior unsecured notes due 2021 issued by Fresenius Medical Care US Finance, Inc. and €300 million of senior unsecured notes due 2021 issued by FMC Finance VII S.A..

21 Jan 2011

St. Jude Medical reaches settlement agreement with DOJ over post-market study matter in Boston

St. Jude Medical, Inc., a global medical device company, today issued the following statement regarding a settlement agreement reached with the U.S. Department of Justice (DOJ) regarding a previously disclosed 2005 investigation in Boston related to an industry-wide review of post-market studies and registries:

21 Jan 2011

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, announced that Teva Pharmaceutical Industries Limited (Teva) purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share.

21 Jan 2011